DrugPatentWatch Database Preview
TPOXX Drug Profile
» See Plans and Pricing
Which patents cover Tpoxx, and when can generic versions of Tpoxx launch?
Tpoxx is a drug marketed by Siga Technologies and is included in one NDA. There are six patents protecting this drug.
This drug has seventy patent family members in twenty-one countries.
The generic ingredient in TPOXX is tecovirimat. One supplier is listed for this compound. Additional details are available on the tecovirimat profile page.
US ANDA Litigation and Generic Entry Outlook for Tpoxx
Tpoxx will be eligible for patent challenges on July 13, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 23, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TPOXX
| International Patents: | 70 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 16 |
| Patent Applications: | 69 |
| DailyMed Link: | TPOXX at DailyMed |
Generic Entry Opportunity Date for TPOXX
Generic Entry Date for TPOXX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for TPOXX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TPOXX
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 105175311 | Start Trial |
| Israel | 241730 | Start Trial |
| Israel | 258239 | Start Trial |
| Mexico | 363189 | Start Trial |
| China | 101702904 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
